Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Adverum Biotechnologies Inc (ADVM)

Adverum Biotechnologies Inc (ADVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 293,476
  • Shares Outstanding, K 20,755
  • Annual Sales, $ 3,600 K
  • Annual Income, $ -117,170 K
  • 60-Month Beta 0.88
  • Price/Sales 84.52
  • Price/Cash Flow N/A
  • Price/Book 1.71
Trade ADVM with:

Options Overview Details

View History
  • Implied Volatility 135.90% ( -11.04%)
  • Historical Volatility 62.94%
  • IV Percentile 22%
  • IV Rank 10.77%
  • IV High 841.56% on 11/29/23
  • IV Low 50.71% on 06/22/23
  • Put/Call Vol Ratio 0.50
  • Today's Volume 69
  • Volume Avg (30-Day) 109
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 9,668
  • Open Int (30-Day) 7,082

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.30
  • Number of Estimates 2
  • High Estimate -1.20
  • Low Estimate -1.40
  • Prior Year -2.90
  • Growth Rate Est. (year over year) +55.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.67 +3.44%
on 03/26/24
20.90 -32.34%
on 03/08/24
-5.56 (-28.22%)
since 02/28/24
3-Month
7.40 +91.08%
on 12/29/23
29.70 -52.39%
on 02/08/24
+6.58 (+87.04%)
since 12/28/23
52-Week
6.81 +107.64%
on 04/10/23
29.70 -52.39%
on 02/08/24
+6.14 (+76.75%)
since 03/28/23

Most Recent Stories

More News
Adverum Biotechnologies: Q4 Earnings Snapshot

Adverum Biotechnologies: Q4 Earnings Snapshot

ADVM : 14.14 (-3.55%)
Adverum Biotechnologies: Q3 Earnings Snapshot

Adverum Biotechnologies: Q3 Earnings Snapshot

ADVM : 14.14 (-3.55%)
Adverum Biotechnologies: Q2 Earnings Snapshot

Adverum Biotechnologies: Q2 Earnings Snapshot

ADVM : 14.14 (-3.55%)
Adverum Biotechnologies: Q1 Earnings Snapshot

Adverum Biotechnologies: Q1 Earnings Snapshot

ADVM : 14.14 (-3.55%)
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?

Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.

ADIL : 1.3300 (-5.00%)
ADVM : 14.14 (-3.55%)
Rumble, Braze rise; Virgin Orbit, Sientra fall

Stocks that traded heavily or had substantial price changes Friday: Rumble, Braze rise; Virgin Orbit, Sientra fall

ADVM : 14.14 (-3.55%)
SIEN : 0.1740 (-18.69%)
BB.TO : 3.71 (-0.54%)
NKLA : 1.0400 (+14.40%)
Adverum Biotechnologies: Q4 Earnings Snapshot

Adverum Biotechnologies: Q4 Earnings Snapshot

ADVM : 14.14 (-3.55%)
Adverum Biotechnologies: Q3 Earnings Snapshot

Adverum Biotechnologies: Q3 Earnings Snapshot

ADVM : 14.14 (-3.55%)
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study

Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.

REGN : 962.49 (-0.39%)
DVAX : 12.41 (unch)
BAYRY : 7.6600 (-0.13%)
ADVM : 14.14 (-3.55%)
Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference

REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish...

ADVM : 14.14 (-3.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum's core capabilities include clinical development,...

See More

Key Turning Points

3rd Resistance Point 15.68
2nd Resistance Point 15.25
1st Resistance Point 14.69
Last Price 14.14
1st Support Level 13.71
2nd Support Level 13.28
3rd Support Level 12.72

See More

52-Week High 29.70
Fibonacci 61.8% 20.96
Fibonacci 50% 18.26
Fibonacci 38.2% 15.55
Last Price 14.14
52-Week Low 6.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar